Positioning of proteasome inhibitors in therapy of solid malignancies

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• The ubiquitin-proteasome system (UPS) is a key cellular pathway regulating protein degradation.
• Targeting the UPS with proteasome inhibitors has shown efficacy in hematological malignancies.
• Growing interest exists in applying proteasome inhibitors to solid tumor treatment.

Purpose of the Study:

• To review the current clinical applications of proteasome inhibitors in common solid tumors.
• To discuss the mechanisms of action and resistance to proteasome inhibitors in solid tumors.
• To identify predictive factors for proteasome inhibitor therapy in solid malignancies.

Main Methods:

• Literature review of preclinical and clinical studies on proteasome inhibitors in solid tumors.
• Analysis of data on efficacy, safety, and resistance mechanisms.
• Synthesis of information on predictive biomarkers and therapeutic strategies.

Main Results:

• Proteasome inhibitors are being investigated for lung, colon, pancreatic, breast, and head and neck cancers.
• Understanding resistance mechanisms is crucial for optimizing treatment.
• Predictive factors are being identified to guide patient selection.

Conclusions:

• Proteasome inhibitors represent a promising therapeutic avenue for solid tumors.
• Further research is needed to overcome resistance and establish optimal treatment protocols.
• Personalized approaches based on predictive factors may enhance patient outcomes.